Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sosei Group ( (JP:4565) ) has shared an announcement.
Nxera Pharma has signed an exclusive licensing agreement with Switzerland’s Santhera Pharmaceuticals to develop, manufacture and commercialize vamorolone, marketed as AGAMREE for Duchenne muscular dystrophy (DMD), in Japan, South Korea, Australia and New Zealand. Vamorolone, already approved in the US, EU, UK and China, has shown a substantially improved safety profile over conventional corticosteroids, including fewer vertebral fractures, a lower incidence of cataracts and preserved normal growth, while maintaining comparable efficacy, positioning it as a potential replacement for current steroid therapies in DMD. Under the deal, Nxera will handle regulatory approvals, any required clinical trials, and commercialization in the licensed territories, leveraging prior development and manufacturing experience gained via its 2023 acquisition of Idorsia’s Japan and APAC business. Nxera will pay Santhera an upfront USD 40 million (USD 30 million in cash and USD 10 million as a strategic equity investment), plus up to USD 165 million in sales and regulatory milestones and tiered royalties starting in the low teens, underscoring the strategic importance of vamorolone in expanding Nxera’s late- and commercial-stage pipeline and strengthening its position as a key rare-disease player in the APAC DMD market.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen718.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma, listed on the Tokyo Stock Exchange, is a Japanese biopharmaceutical company focused on bringing innovative medicines for rare and specialty diseases to Japan and the broader Asia-Pacific region. Its portfolio already includes PIVLAZ (clazosentan) and QUVIVIQ (daridorexant), which are approved and marketed in Japan and being developed commercially in other APAC markets, supporting the company’s strategy to build a high-growth, highly profitable regional biopharma platform by 2030.
Average Trading Volume: 914,410
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen78.64B
For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.